2023至2024年巴西奥罗普切病毒再现:一项观察性流行病学研究
该观察性流行病学研究结合巴西奥罗普切病毒感染的多源数据,发现2015年1月4日至2024年8月10日实验室确诊的10557例中8639例(81.8%)发生于2024年,为年例数中位数147例的58.8倍;体外实验提示新重配株AM0088复制效率更高且既往免疫中和能力较低。
要点
- 2024年巴西奥罗普切热病例数达8639例,为年例数中位数147例的58.8倍。
- 所有27个联邦单位均有报告,北巴西占8182/10557例(77.5%)。
- 2024年1月1日至2月4日亚马逊州93例急性发热患者中10例(11%)检出奥罗普切病毒RNA。
核心结论
- 这些发现全面评估了巴西奥罗普切热,并增进了对2023至2024年奥罗普切病毒再现的理解。
- 探索性体外数据提示发病率增加可能与新奥罗普切病毒重配株复制效率更高、既往免疫对其中和能力较低有关。
研究设计与样本
- 观察性流行病学研究,结合巴西奥罗普切病毒感染的多源数据并进行体外和体内表征。
- 血清样本来自巴西亚马逊州马瑙斯市18岁及以上、疟疾检测阴性的急性发热患者,以及亚马逊州科阿里市既往奥罗普切病毒感染者的样本。
- 从巴西实验室环境管理系统收集基本临床和人口学数据,使用巴西卫生部和2022年巴西人口普查数据计算发病率。
- 采用逆转录定量PCR检测奥罗普切病毒RNA,随后对病毒分离株进行测序和系统发育分析。
- 通过滴度、蚀斑数和蚀斑大小比较2023至2024年流行分离株AM0088与历史原型株BeAn19991的表型,并用PRNT50评估中和敏感性。
主要发现
- 2015年1月4日至2024年8月10日实验室确诊的10557例奥罗普切热病例中,8639例(81.8%)发生于2024年,为年例数中位数147例(IQR 73-325)的58.8倍。
- 所有27个联邦单位均有奥罗普切病毒感染报告,其中北巴西发生8182/10557例感染(77.5%)。
- 2024年1月1日至2月4日亚马逊州93例急性发热患者中,10例(11%)检出奥罗普切病毒RNA。
- AM0088在感染哺乳动物细胞后12小时和24小时的复制显著高于原型株。
- AM0088在哺乳动物细胞中表型比原型株更具毒力,表现为蚀斑形成更早、蚀斑数增加27%至65%、蚀斑大2.4至2.6倍。
关键数值与推荐
- 2024年奥罗普切热病例数8639例,为年例数中位数147例(IQR 73-325)的58.8倍。
- 北巴西感染8182/10557例(77.5%),所有27个联邦单位均有报告。
- 2024年1月1日至2月4日亚马逊州93例急性发热患者中10例(11%)检出病毒RNA。
- AM0088较原型株蚀斑数增加27%至65%,蚀斑大2.4至2.6倍。
- 2016年5月2日和5月20日采集的既往感染者血清对AM0088的中和能力较原型株至少降低32倍(BeAn19991中位PRNT50滴度640[IQR 320-640] vs AM0088 <20[低于检测限])。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Oropouche virus is an arthropod-borne virus that has caused outbreaks of Oropouche fever in central and South America since the 1950s. This study investigates virological factors contributing to the re-emergence of Oropouche fever in Brazil between 2023 and 2024. METHODS: In this observational epidemiological study, we combined multiple data sources for Oropouche virus infections in Brazil and conducted in-vitro and in-vivo characterisation. We collected serum samples obtained in Manaus City, Amazonas state, Brazil, from patients with acute febrile illnesses aged 18 years or older who tested negative for malaria and samples from people with previous Oropouche virus infection from Coari municipality, Amazonas state, Brazil. Basic clinical and demographic data were collected from the Brazilian Laboratory Environment Management System. We calculated the incidence of Oropouche fever cases with data from the Brazilian Ministry of Health and the 2022 Brazilian population census and conducted age-sex analyses. We used reverse transcription quantitative PCR to test for Oropouche virus RNA in samples and subsequently performed sequencing and phylogenetic analysis of viral isolates. We compared the phenotype of the 2023-24 epidemic isolate (AM0088) with the historical prototype strain BeAn19991 through assessment of titre, plaque number, and plaque size. We used a plaque reduction neutralisation test (PRNT50) to assess the susceptibility of the novel isolate and BeAn19991 isolate to antibody neutralisation, both in serum samples from people previously infected with Oropouche virus and in blood collected from mice that were inoculated with either of the strains. FINDINGS: 8639 (81·8%) of 10 557 laboratory-confirmed Oropouche fever cases from Jan 4, 2015, to Aug 10, 2024, occurred in 2024, which is 58·8 times the annual median of 147 cases (IQR 73-325). Oropouche virus infections were reported in all 27 federal units, with 8182 (77·5%) of 10 557 infections occurring in North Brazil. We detected Oropouche virus RNA in ten (11%) of 93 patients with acute febrile illness between Jan 1 and Feb 4, 2024, in Amazonas state. AM0088 had a significantly higher replication at 12 h and 24 h after infection in mammalian cells than the prototype strain. AM0088 had a more virulent phenotype than the prototype in mammalian cells, characterised by earlier plaque formation, between 27% and 65% increase in plaque number, and plaques between 2·4-times and 2·6-times larger. Furthermore, serum collected on May 2 and May 20, 2016, from individuals previously infected with Oropouche virus showed at least a 32-fold reduction in neutralising capacity (ie, median PRNT50 titre of 640 [IQR 320-640] for BeAn19991 vs <20 [ie, below the limit of detection] for AM0088) against the reassortant strain compared with the prototype. INTERPRETATION: These findings provide a comprehensive assessment of Oropouche fever in Brazil and contribute to an improved understanding of the 2023-24 Oropouche virus re-emergence. Our exploratory in-vitro data suggest that the increased incidence might be related to a higher replication efficiency of a new Oropouche virus reassortant for which previous immunity shows lower neutralising capacity. FUNDING: São Paulo Research Foundation, Burroughs Wellcome Fund, Wellcome Trust, US National Institutes of Health, and Brazilian National Council for Scientific and Technological Development. TRANSLATION: For the Portuguese translation of the abstract see Supplementary Materials section.
引用
- Scachetti GC, Forato J, Claro IM, et al. Re-emergence of Oropouche virus between 2023 and 2024 in Brazil: an observational epidemiological study. Lancet Infect Dis. 2024. PMID: 39423838. doi:10.1016/S1473-3099(24)00619-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。